Site4Drug: Predicting Drug-Binding Target Sites with an AI Agent
Taehan Kim †, Sarrah Rose Mikhail Leung, Bharat Mekala, Jeongbin Park † · 2026
Read Site4Drug: Predicting Drug-Binding Target Sites with an AI Agent by Taehan Kim †, Sarrah Rose Mikhail Leung, Bharat Mekala, Jeongbin Park † (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/arxiv-2606-01816.txt.
Introduction
Kim and co-authors target a hard first step in drug design. A drug must bind a protein at the right site. Picking that site is vague and prone to failure. Membrane proteins add limits from shape and access. Marks added after the protein is built also matter.
Their Site4Drug agent ranks sites that a drug could reach. Each rank comes with limits, proof notes, and risk flags. A clear log traces each choice step by step. The agent can also suggest a drug type. It may favor a large antibody-like drug or a small one. The same proof guides all site picks. That blocks sites that look fine but stay sealed off.
Catalog record
| CREATOR | Taehan Kim †, Sarrah Rose Mikhail Leung, Bharat Mekala, Jeongbin Park † |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 55 KB |
| LICENSE | http://creativecommons.org/licenses/by/4.0/ |
| RIGHTS | CC BY |
| SOURCE | arXiv |
Source: https://arxiv.org/abs/2606.01816
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Site4Drug: Predicting Drug-Binding Target Sites with an AI Agent Taehan Kim †, Sarrah Rose Mikhail Leung, Bharat Mekala, Jeongbin Park † Abstract Selecting where to intervene on a protein (i.e., choosing a targetable site ) is often a more ambiguous and failure-prone bottleneck than selecting what binds, especially for membrane proteins where accessibility, topology, and post-translational modifications (PTMs) constrain actionable regions. We present Site4Drug , a modality-aware site-finding agent that outputs a ranked list of targetable regions with explicit constraints, evidence summaries, risk flags, and a traceable decision log. Rather than requiring users to specify the drug modality upfront, Site4Drug can recommend a binding modality (e.g., antibody/peptide-like vs small-molecule) from the same evidence used for site discovery, including topology, hydropathy, PTM propensity, disulfides, domain context, and sequence. Importantly, this evidence is applied consistently across modalities, including small-molecule pocket discovery, to avoid selecting chemically plausible but biologically occluded sites. 1 Introduction Many discovery pipelines assume a binding site is known and focus on docking, screening, or binder generation. For example, this includes models like BoltzGen ( 16 ) for binder generation and CLIP-style pocket scoring models (e.g., DrugCLIP ( 6 ) , BindCLIP ( 15 ) ) that evaluate candidates given a predefined site. In practice, teams often stall earlier: where and with what modality should we target on the protein? For membrane proteins this is especially difficult: only certain regions are physically accessible, topology predictions can disagree, and PTMs (notably glycosylation) can occlude or destabilize candidate epitopes. When downstream screening fails, teams may not know whether the binding model failed or the site choice was wrong, partly because the reasoning behind site selection is rarely logged or can be arbitrary. Curated resources can help, but they are not absolute ground truths for therapeutic site selection. For example, IEDB ( 18 ) aggregates immune epitope evidence from highly specialized experimental settings (e.g., T cell and B cell assays) that are context-dependent and inherently incomplete; critically, these assays were not designed to exhaustively enumerate drug-actionable binding sites on proteins. On the small-molecule side, “known pockets” are often operationally defined by taking residues contacting a co-crystallized ligand and padding by a fixed neighborhood. Such definitions can be brittle: a limited number of known ligand-bound structures leaves the pocket undefined (no prior discoveries). This is particularly important for cancer neoantigens and mutated viral antigens. Together, these limitations motivate epitope/pocket discovery that is grounded in feasibility constraints along with reasoning traces. Conventional approaches such as fpocket ( 12 ) and RAPID-Net ( 3 ) rely on geometric features or learned structural representations, and thus can primarily be applied to the identification of canonical binding pockets. As a result, they are limited in their ability to incorporate diverse metadata or to define sites for alternative drug modalities. Recently, large language models (LLMs) have been increasingly utilized in tasks such as protein structure prediction and drug-genomic response prediction. Moreover, their ability to flexibly integrate diverse forms of unstructured data suggests that they should be considered for adoption in site definition tasks. Additionally, LLM-based AI agentic systems are being introduced into AI-driven scientific discovery research (e.g., AI-Descartes ( 4 ) , Theorizer ( 9 ) , AutoDiscovery ( 2 ) , The AI Scientist ( 13 ) , AI co-scientist ( 8 ) , The Virtual Lab ( 17 ) ), because they require repeated execution of LLMs to achieve reproducible scientific conclusions. Therefore, we explore the potential of drug site detection as an LLM agentic system. Figure 1 : Site4Drug discovers a potential binding region for binder design. Thus, Site4Drug attempts to provide a solution for the upstream bottleneck. It reframes site selection as a constraint-first, evidence-integrated decision problem . Given a protein sequence, it proposes candidate regions, ranks them, and emits a structured report: what constraints were applied, what evidence supported each candidate, and what risks remain. This makes the site-selection step auditable and debuggable. With these results, third-party tools can also be invoked as part of an agentic system as summarized in Figure 1 . 2 Problem Setup 2.1 Inputs and Outputs Input. A target protein specified by an amino-acid sequence x_{1:L} . Output. Site4Drug returns a structured, auditable site-selection result consisting of: • Recommended binding modality: a categorical recommendation \hat{m}\in\{\textsf{epitope},\textsf{pocket},\textsf{other}\} with an evidence-backed rationale and uncertainty notes. 1 1 1 Epitope refers to where antibodies or peptide binders attach, usually on extracellular protruding regions of membrane proteins and often tied to immune responses. Pocket refers to where small molecules bind, typically in intracellular proteins or membrane channels, covering immune as well as general signaling and metabolic pathways. Other covers cases where the evidence suggests non-standard or mixed modes (e.g., ambiguous accessibility or competing feasibility constraints). • Ranked candidates with scores: a list of K candidates \{r_{k}\}_{k=1}^{K} with per-candidate score S(r_{k}) : – Accessibility/topology label: a coarse label derived from hydropathy and transmembrane (TM) overlap; – Evidence summary: key signals supporting or penalizing the region (hydropathy, TM overlap, typed PTM masks, motif hits, cysteine/disulfide context); – Flags: typed annotations including risk flags (e.g., “TM-overlap”, “PTM-overlap”, “glyco-mask-overlap”, “disulfide-constrained”, “motif-overlap”) A representative output report is shown in the Appendix A , Fig. S1 . 2.2 Method Overview: Two Modules Site4Drug potentially offers two modules: 1. Module 1 (Main Discovery Engine): evidence extraction \rightarrow constraint-first candidate generation \rightarrow scoring/ranking with risk flags and audit log. 2. Module 2 (Potential Design Handoff): route top candidates to modality-appropriate downstream design/scoring tools (e.g., peptide-binder generation in epitope mode; pocket-aware ligand scoring in pocket mode). Figure 2 : Two-module pipeline: constraint-first discovery (Module 1) followed by modality-specific design handoff (Module 2). 3 Module 1: Evidence Aggregation and Region Discovery As summarized in Figure 2 , Module 1 constructs a residue- and region-level evidence summary from three signal classes: i) topology/accessibility priors, ii) PTM risk signals, and iii) motif/domain context. These signals are used to guide 1) binding site candidate proposal, 2) validate proposed spans, and 3) attach interpretable risk annotations. 3.1 Evidence Extractors Given a protein sequence, Site4Drug computes three classes of feasibility-aware signals that are exposed to the proposal stage and retained for downstream validation. I. Coarse topology + hydropathy. Site4Drug computes a sliding-window Kyte–Doolittle hydropathy profile ( 11 ) together with a heuristic TM detector to derive a coarse accessibility prior from sequence alone. Regions overlapping detected TM segments are labeled tmd / restricted , whereas non-overlapping regions are labeled outside / exposed , with confidence determined by the hydropathy margin from the TM threshold. II. PTM prediction + neighborhood masking. Site4Drug uses PTM calls as feasibility constraints of targetability. PTM sites are obtained from a MusiteDeep-backed extractor ( 19 ) with rule-based augmentation, and each site is expanded into a typed local mask. We then record whether a candidate overlaps these masks, together with overlap counts by PTM type and local PTM density. For example, if MusiteDeep predicts a phosphoserine/phosphothreonine site at residue 211, we expand it into a typed local mask (e.g., residues 208–214) and record whether a candidate region overlaps that mask. III. Motif hits + cysteine/disulfide proxy. Site4Drug also queries ScanProsite ( 5 ) and records motif spans as cautionary context for targetability. Overlap with a known motif yields a motif-overlap annotation, since such regions may